Nava Health MD, LLC
NAVA
NASDAQ0.00
USD
- -
- -
CIK
0001932231
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- India
- IPO Date
- Jan 27, 2016
- CIK
- 0001932231
- Similar Companies
- Business
- Nava Health MD LLC (NAVA) operates as a vertically integrated tech-enabled healthcare practice specializing in integrative functional preventive and regenerative medicine with a focus on root-cause solutions longevity optimization and personalized wellness plans. The company provides bioidentical hormone replacement therapy; regenerative therapies including platelet-rich plasma procedures and hyperbaric oxygen therapy; aesthetic services such as Botox dermal fillers and body sculpting; functional nutrition and medically supervised weight loss programs; diagnostic testing via in-house CLIA-certified labs covering chemistry hematology immunoassay genetic and food sensitivity panels; IV micronutrient therapy light therapy bioenergetics and B-12 injections; therapeutic massage acupuncture and stress management; along with premium nutraceuticals under the Nava Elements brand featuring daily multi-supplement packs like Select Select + Weight Loss and Select + Sport. Founded in 2014 and headquartered in Columbia Maryland Nava Health serves clients through physical centers in Maryland Washington DC Northern Virginia Florida and additional locations with telehealth options targeting individuals seeking holistic alternatives for issues like fatigue insomnia anxiety digestive problems menopause weight gain and hormonal imbalances. Recent developments include securing a multimillion-dollar revenue-based financing package from Decathlon Capital Partners in April 2024 to fuel growth initiatives; announcing expansion to Annapolis Maryland in August 2024 amid rising demand for longevity services; experiencing 81% revenue growth to approximately $24.8 million in 2023 driven by higher customer visits and improved per-location economics averaging over $6 million; pursuing national scaling with eight new leased sites planned for 2024 alongside further openings in 2025; and entering a February 2024 merger agreement with 99 Acquisition Group valued at $320 million which was terminated in August 2024 resulting in a $300000 payment to Nava for transaction costs.
Navamedic ASA Q1 2023: Another strong quarter
Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB
U.S. IPO Weekly Recap: February Closes Out With One Micro-Cap As IPO Calendar Gets A Boost
U.S. IPO Weekly Recap: No IPOs, But Pipeline Gets A $350 Million Pick Up From Cummins Spin-Off Atmus